A recent study published by the journal J-Stage as well as the National Institute of Health has found that cannabidiol – a compound found in cannabis – is effective at blocking a certain enzyme which is known to cause cancer, and is produced in large amounts when cigarettes are consumed. THC (delta-9-tetrahydrocannabinoand) and CBE (cannabielsoin) were also found to be effective at preventing this enzyme.
“These results suggest that the pentylresorcinol structure in CBD [cannabidiol] may have structurally important roles in direct CYP1A1 inhibition, although the whole structure of CBD is required for overall inhibition”, according to researchers.
CYP1A1 is an enzyme which isn’t dangerous at low-levels, but is produced in large quantities when someone smokes cigarettes; at large doses, the enzyme has an undeniably linked to cancer.
Researchers state that; “Therefore, CBD and its structurally related compounds which potently inhibit CYP1A1 activity would be expected as a lead compound in anticancer chemotherapy.”
The study was funded by the Ministry of Education, Culture, Sports, Science and Technology of Japan, and was conducted by researchers at the Faculty of Pharmaceutical Sciences at Japan’s Hokuriku University.